Prof. Roman Vangoitsenhoven speaks about a newly published research paper in Obesity Facts sheds light on the real-world effectiveness and practicality of the liraglutide treatment.

Video: https://congressreport.eu/scientific-contents/standalonecontent:liraglutide-weight-management-real-world

Dr. Alexander Miras is a senior lecturer and consultant in endocrinology at Imperial College London, known expert in the field of pediatric medicine.

Video: https://congressreport.eu/scientific-contents/standalonecontent:clinical-impact-liraglutide-treatment-obesity

Prof. Michael A. Nauck has a long clinical experience with GLP-1 analogs, author of several scientific papers about their applications. 

Video: https://congressreport.eu/scientific-contents/standalonecontent:role-glp-1-receptor-agonists-weight-reduction-and-cardiovascular-risk-reduction

Prof. Mikael Rydén speak about the state-of-the-art treatment of the disease.

Video: https://congressreport.eu/scientific-contents/interview:current-guidelines-diabetes-management

Prof. Brian Frier speak about the latest findings on the treatment of the disease.

Video: https://congressreport.eu/scientific-contents/interview:current-guidelines-diabetes-management

Prof. Christoph Wanner speaks about the latest guidelines and findings on treatment and comprehensive care for diabetes.

Video: https://congressreport.eu/scientific-contents/interview:current-guidelines-diabetes-management

Prof. Gabriel N. Hortobagyi speaks about the overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative advanced breast cancer treated with endocrine therapy ± ribociclib.

Video: https://congressreport.eu/scientific-contents/interview:monaleesa-2-trial

Prof. Peter Galle speaks about the  the emerging therapies on advanced RCC, HCC and DTC.

Video: https://congressreport.eu/scientific-contents/interview:spotlight-emerging-therapies-multidisciplinary-discussions-advanced-rcc-hcc-and-dtc

Prof. David F. McDermott speaks about the long-term survival of patients with kidney cancer.

Video: https://congressreport.eu/scientific-contents/interview:should-cure-be-reasonable-goal-arcc

Prof. Jason J. Luke speaks about the efficacy and safety results from the  Keynote 716 double-blinded phase III trial. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma. 

Video: https://congressreport.eu/scientific-contents/interview:keynote-716-trial